Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply
- PMID: 29800980
- DOI: 10.1001/jamapediatrics.2018.0733
Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply
Erratum in
-
Missing Potential Conflict of Interest.JAMA Pediatr. 2018 Sep 1;172(9):891. doi: 10.1001/jamapediatrics.2018.2494. JAMA Pediatr. 2018. PMID: 30073318 Free PMC article. No abstract available.
Comment in
-
Inconsistent Reporting of Potential Conflicts of Interest.JAMA Pediatr. 2018 Sep 1;172(9):886. doi: 10.1001/jamapediatrics.2018.2420. JAMA Pediatr. 2018. PMID: 30073291 No abstract available.
Comment on
-
Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?JAMA Pediatr. 2018 Feb 1;172(2):123-125. doi: 10.1001/jamapediatrics.2017.4360. JAMA Pediatr. 2018. PMID: 29228077 No abstract available.
-
Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy.JAMA Pediatr. 2018 Jul 1;172(7):701. doi: 10.1001/jamapediatrics.2018.0772. JAMA Pediatr. 2018. PMID: 29801053 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical